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Abstract
Before 1990, options were limited for couples who were at risk for transmitting a genetic disease or a structural chromosomal
abnormality to their children. Couples traditionally underwent invasive procedures such as amniocentesis and chorionic villus sampling, after which termination was offered if the fetus was found to be affected. Many couples chose not to have children at all.
Since then, technological advances have allowed preimplantation genetic testing (PGT) to be offered to these couples. Couples who
choose PGT undergo in-vitro fertilization (IVF) with intracytoplasmic sperm injection (ICSI), where the oocyte is injected by a single
sperm and is then implanted into the mother a few days later. However, in PGT, a few cells are removed and genetically analyzed
before implantation to determine whether the embryo has a specific genetic defect or aneuploidy. The purpose of this paper is
to determine whether PGT causes adverse clinical outcomes by critically analyzing PGT research studies. Current research does
not seem to show any major adverse clinical outcomes after PGT especially in cases of singleton pregnancies. It is important to
continue to examine the effects of an embryo biopsy in terms of neonatal and obstetric outcomes, as well as future development.
Introduction
Preimplantation genetic testing (PGT) has become an
integral part of assisted reproductive technology (ART)
and over a third of ART Centers in the United States are
utilizing PGT technology (Kuliev, Rechitsky, 2017). There
are three kinds of PGT.The first, PGT-M, analyzes the embryo for monogenic diseases. This is generally used when
one or both parents carry a mutation, such as those
linked to Huntington’s disease or cystic fibrosis. Testing is
performed to ensure the single-gene trait has not been
passed to the embryo. It is often used after a previous
child has been diagnosed with a specific genetic condition.
PGT-M may also be used for sex selection, such as when
a parent is a carrier of an x-linked disorder (Pastore, et.
al. 2019). The second, PGT-A, and third, PGT-SR, are not
standard procedures and were developed to improve the
success rate of IVF. PGT-A is used to look for embryonic aneuploidy and PGT-SR is used to look for chromosomal structural rearrangements such as inversions
or translocations. PGT-A and PGT-SR are usually only
recommended in cases of previous failed rounds of IVF,
severe male infertility, recurrent pregnancy loss, in cases
where one or both parents have a balanced chromosome
structural rearrangement, or for patients at high risk for
embryo aneuploidy, such as those of advanced maternal
age.While all forms of PGT come with many ethical questions, in general PGT-M is considered more acceptable,
especially when it is used to prevent severe genetic diseases with few treatment options. Genetic counseling is
recommended before any form of PGT to ensure that
the couple understands the risks and limitations of the
procedure (Eskew, Jungheim, 2017).
There are multiple methods of performing PGT. Polar
body biopsy (PBB) is a common method for genetically analyzing an embryo. Polar bodies are formed during
meiosis of an oocyte and are not required for fertilization or embryo development. Therefore, they can be removed safely and screened without harming the embryo.

Additionally, PBB avoids errors due to the presence of
mosaicism that other methods of PGT incur. Mosaicism is
when different cells have different genotypes within one
organism and is not present at the zygote stage. PBB is
considered a less invasive procedure and is a good option
for patients who view more invasive procedures as unethical. However, PBB can only provide maternal genetic
information. Because PBB does not include paternal genetic information and cannot be used to determine gender, this method can only work in certain cases (Schenk,
et. al. 2018).
PGT can also be done through a blastomere biopsy
during the cleavage stage. This is done three days after
fertilization, when the embryo is between six to eight
cells. A blastomere biopsy is an invasive procedure where
cell-to-cell adhesions are loosened and one or two blastomeres are aspirated. The blastomeres are then genetically analyzed for either aneuploidy or specific genetic
mutations (Kalma, et. al. 2018). A blastomere biopsy allows both maternal and paternal genetic information to
be analyzed, which makes determining the gender of the
embryo possible. However, given that this is an invasive
procedure, this method may affect the growth and development of the embryo.While there is evidence that a day
three embryo can tolerate and overcome the possible
resultant damage, it is likely that embryos that would otherwise progress to implantation will be lost at this stage
of embryo development.Additionally, a blastomere biopsy
may not always be reliable since it is affected by both the
technical and biological problems associated with single
cell analysis. Specifically, mosaicism, which is at the highest level at this stage of development, can lead to false
positive and false negative errors. In order to compensate, two blastomeres can be removed. While this may
increase the accuracy of the genetic testing, around 25%
of the embryonic mass is removed, which may impact
clinical outcomes (Cimadomo, et. al. 2016).
A third method of PGT is a blastocyst biopsy. It is
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usually done five to six days after fertilization, when the
embryo is about one hundred cells. During a blastocyst
biopsy, five to six cells of the trophectoderm are removed
and analyzed. This method allows more cells to be tested, compared to the only one or two cells that can be
removed during a blastomere biopsy, and allows for improved accuracy of the genetic testing. Additionally, this
procedure removes a smaller proportion of embryo cell
mass when compared to the day three biopsy and only
removes cells from the trophectoderm, not the inner
cell mass. However, blastocyst biopsies have limitations
as well. Only 50% of IVF embryos develop to the blastocyst stage and waiting for a day five biopsy may result in
no transfer at all. Additionally, following a day five biopsy,
embryos typically need to be cryopreserved and then
thawed which precludes the transfer of a fresh embryo.
While there are many methods of performing PGT, each
method has its own benefits and limitations (Wang, et. al.
2018). Once the cells are removed, they are genetically
analyzed by either polymerase chain reaction (PCR), fluorescence in situ hybridization (FISH), array-comparative
genomic hybridization, and more recently, next-generation sequencing, in order to determine if there are any
genetic defects (Heijligers, et. al. 2018).
Because PGT is an invasive procedure, researchers have
wondered if it increases the risk of adverse clinical outcomes. It is especially important to monitor the safety of
PGT since the majority of the PGT couples, specifically
couples undergoing PGT-M, have no fertility issues and have
the alternative of a natural conception with or without invasive prenatal testing. This review is aimed at determining
whether PGT increases the risk of adverse obstetric and
neonatal clinical outcomes as well as future development.
Methods
The research discussed in this paper was collected using
EBSCO, ProQuest, PubMed and Google Scholar with access provided by the Touro College Library. All articles
included are original, peer reviewed research papers that
were analyzed to ensure accurate data.
Discussion
Neonatal Outcomes
Malformation/ Perinatal Death
A study was aimed at evaluating the safety of PGT and
focused on the rate of congenital malformations as well
as other adverse perinatal outcomes. In this study, embryos for PGT analysis were produced by intracytoplasmic
sperm injection (ICSI) and subjected to blastomere biopsy. Parents filled out a questionnaire regarding their pregnancy and the health of their child. Medical information,
6

such as age of both parents at embryo transfer, gravidity, parity, number of previous in vitro fertilization (IVF)/
PGT cycles, whether the embryo(s) was fresh or frozen/
thawed, how many blastomeres had been removed, and
how many embryos were transferred, was also obtained
from their doctor. The largest proportion of couples in
this study opted for PGT-M, in order to avoid passing an
autosomal dominant disease to the child. In this study,
more girls than boys were born after PGT with a ratio
of 1.2. This may be due to sex-selection, where a female
embryo is transferred to reduce the risk of inheriting an
X-linked condition. Major congenital malformations were
found in nine of the 364 live births (2.5%). Four of these
children had multiple congenital anomalies and five children (1.4%) had minor malformations. Three pregnancies
were terminated because of diagnoses of exencephaly,
trisomy 18, and trisomy 21. The major malformation rate
when including pregnancy terminations due to congenital malformations was 3.3%. A report by the European
Surveillance of Congenital Anomalies stated a prevalence
of 261.45 major and minor birth anomalies per 10,000
births (2.6%) between 2008 and 2012, which is similar
to the rate in this study. According to these results, the
risk of major malformations in children born after PGT
does not seem to be increased when compared to the
general population. The study also found that perinatal
deaths were reported in 3 out of 364 PGT pregnancies
studied.Two of the pregnancies were of a twin and a triplet. Additionally, at 37 weeks gestational age, a singleton
was stillborn, after an uncomplicated pregnancy. With a
perinatal mortality rate of 0.8%, no evidence for a potential increased risk in fetal or neonatal death was found
after PGT (Heijligers, et. al. 2018).
Similar results were found in a study that looked at the
health of 49 children conceived after PGT compared to
66 naturally conceived (NC) controls. Control children
were matched for age, sex, ethnicity, maternal educational
level and socioeconomic status. A majority of PGT subjects had undergone PGT-A, however the study did not
distinguish between subjects who had undergone PGTM, PGT-A, or PGT-SR. However, all PGT subjects were
born after an embryo biopsy at the eight to ten cell stage.
Pediatricians that assessed the children were blinded to
the conception status of the children, strengthening the
results of this study. The study found that two children
born after PGT had congenital anomalies, one with a
minor ear deformity and the other with mild hypospadias
(Banerjee, et. al. 2008).
Another study examined whether PGT blastomere biopsies impacted the health of infants up to two months of
age by comparing the data of 995 children born after PGT
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and 1507 children born after IVF and ICSI. Twenty-three
PGT children (2.3%) and 40 ICSI children (2.7%) presented major malformations. Major genital malformations
were recorded in seven PGT children and 9 ICSI children.
Four stillborns conceived after PGT and seven stillborns
conceived after ICSI presented major malformations. The
total major malformation rate, including stillborn and live
born, was comparable in the PGT group (2.6%) and the
ICSI group (3%). These results do not indicate that the
added cleavage-stage biopsy procedure increases the risk
of major birth defects compared to the ICSI procedure
(Desmyttere, et. al. 2012).
In another study, data from the PGT pregnancies of 158
singletons, 42 pairs of twins, and 1 set of triplets was compared to data obtained from 242 children born after IVF/
ICSI and 733 randomly selected NC children born during
the same time period. The mothers in all groups were
matched for age, preconception body mass index, and parity. Data collected included parental demographic information, type of biopsy performed (polar body and/ or blastomere biopsy), number of embryos transferred, whether
the embryo(s) were fresh or frozen/ thawed, gestational
age and mode of delivery. At two to four months, parents
also filled out a questionnaire regarding any malformations
that had not been diagnosed at birth. In both single and
multiple pregnancies, the type of embryo biopsy had no
significant influence the neonatal outcome. Four of the
PGT children (1.7%) presented congenital malformations.
One intrauterine fetal death occurred at 33 weeks with a
subsequent diagnosis of thrombophilia.The congenital malformation rate for PGT pregnancies is similar to the rates
found in other studies (Eldar-Geva, et. al. 2014).Additionally,
in another Israeli study completed around the same time
of 213,288 NC births, the rate of congenital malformations
was 1.9% which is similar to the rate of malformation after
PGT in this study (Farhi, et. al. 2013).
Another study looked at the health of 581 children
born after a blastomere biopsy. Questionnaires were sent
to both physicians and parents at conception and delivery and children were examined at two months of age,
usually by a clinical geneticist. The researchers followed
484 pregnancies, with three terminations for major malformations seen on prenatal ultrasounds. Of these, 385
were singleton pregnancies, 92 were twin pregnancies
and four were triplet pregnancies leading to a total of
581 PGT children. There were no differences in any of
the studied properties between biopsies done for PGT-M
or PGT-A and the results were therefore combined. As
seen in many other studies, sex distribution of live born
children was uneven with 54% girls for 46% boys and is
due to sex selection for X-linked diseases. Of the 581

children in the PGT cohort, eighteen were stillborn and
nine died neonatally. Of these 27 perinatal deaths, four
were in singleton pregnancies and 23 in multiple pregnancies. The rate of perinatal deaths in singletons is comparable to the ICSI cohort, however the ICSI multiple birth
cohort had a higher perinatal death rate. Major malformations were seen in 17 PGT fetuses which led three to
be terminated. This led to a malformation rate in born
and unborn children of 2.9%. Of the fourteen children
with malformations, two were stillborn and both were
from a multiple pregnancy. This leaves one inherited and
eleven sporadic mutations in the 563 PGT children born
alive with a rate of 2.13%. The major malformation rate
in the ICSI cohort was 3.13%. The main finding of this
study is that a day three embryo biopsy does not seem
to increase the risk of major malformations. When these
results are compared with the data collected from IVF/
ICSI children born within the same timeframe, the rate of
malformations is comparable. (Liebaers, et. al. 2010)
Gestational Age/ Birth Weight
Studies also looked at the gestational age and birthweight
of children conceived through PGT. In the study by
Heijligers et al. (2018), eighty percent of the PGT children
were born full term. Eight children, all from twin pregnancies (2.2%), were born very premature (<32 weeks).
The study distinguished very premature children from
premature children to show that the very premature
children were all from twin pregnancies. Less than 15% of
the PGT children had a low birth weight and were either
twins or triplets. Only one singleton had a very low birth
weight. The child was born at 35 weeks through caesarian section because of HELLP syndrome in the mother. A
z-score of + 0.17 was calculated for the singletons which
indicates a comparable birth weight between this cohort
and the rest of the Dutch population. In concordance
with other studies on PGT there is an evident increase in
prematurity and low and very low birth weight in multiples when compared to singletons.This strongly supports
the current Dutch single embryo transfer policy. Overall,
data from this study on pregnancy duration and birth
weight in the Dutch PGT population, especially in the singletons, seems similar to the published data on naturally
conceived children.
In the study performed by Eldar-Geva et. al. (2014),
the difference in mean birth weight for singleton pregnancies between the three groups was statistically significant. Singleton NC children had a significantly higher
birth weight than those born after ICSI (P=.006) but not
compared to the PGT singletons. Low birth weight was
also more frequent in the ICSI group than in the PGT and
7
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NC singletons. Also, significantly more ICSI twins (58%)
presented with low birth weight compared to 41.0% of
PGT twins and 44.2% of NC twins. Very low birth weight
(<1,500 g) was rare in all groups. There was also a statistically significant difference among the groups when
examining intrauterine growth for singleton pregnancies
(P=.001). Intrauterine growth restriction was more frequent in ICSI pregnancies (9.5%) than in NC (5.5%) or
PGT pregnancies (5.1%). Children born large for their
gestational age was more frequent in the PGT group
(16.5%) than the NC group (8.8%). The mean gestational
age, rates of preterm birth and intrauterine growth restriction for twin and triplet pregnancies were similar for
the three groups.
These results show that there are no increased risks of
intrauterine growth restriction or low birth weight in singleton or twin pregnancies after PGT compared to NC.
However, ICSI pregnancies did show an increased risk for
both of these complications. These results remained true
even after controlling for factors such as maternal age,
parity, BMI, number of embryos transferred and whether
the embryo was cryopreserved, which can affect pregnancy outcomes. The increased likelihood of adverse
outcomes in ICSI pregnancies may be due to the fertility
status of the parents. Infertile women are more prone
to adverse outcomes even when conceiving naturally, indicating that infertility itself is what increases the risk of
adverse outcomes such as low birth weight and preterm
delivery (Basso, Baird, 2003). This may explain the similarity of the results in birth weight and intrauterine growth
from PGT and NC pregnancies, since the majority of PGT
couples usually do not struggle with fertility.
The difference in pregnancy duration for singleton
pregnancies between the three cohorts was also statistically significant. NC pregnancies were longer, than both
the PGT and the ICSI pregnancies. However, for the PGT
group, these findings had no clinical significance because
the frequency of preterm deliveries, both <37 (7.4%) and
<34 weeks (1.3%) was comparable with NC pregnancies
(5.7% and 2.0%, respectively). However, 11.4% of the ICSI
cohort were born prematurely. PGT and ICSI pregnancies
may have been shorter for different reasons.Women who
undergo PGT are at high risk for autosomal recessive,
X-linked, or dominant genetic disease and therefore have
a higher incidence of previous pregnancy terminations for
affected fetuses. Complications associated with induced
abortions include premature delivery of future children
and cervical incompetence. Additionally, some of the PGT
women in the study had autosomal dominant diseases
such as myotonic dystrophy, achondroplasia, neurofibromatosis and tuberous sclerosis and because of this chose
8

to have a cesarean delivery at 37 to 38 weeks. In fact,
the PGT cesarean delivery rate was more than double in
PGT pregnancies. Additionally, some of the families had
critically ill children which may have placed an emotional
and physical burden on the family and pregnant mother
(Eldar-Geva, et. al. 2014). The preterm birth rate for the
IVF/ ICSI group is unsurprising. As discussed above many
studies have found that preterm birth is associated with
children conceived through IVF/ ICSI because of the parents underlying fertility issues (Wisborg, et. al. 2010).
Another study looked at the health of 49 PGT children
and 66 NC children. The PGT cohort had a significantly lower gestational age at birth (P = 0.0001) and more
preterm births than the NC group. The PGT group was
also more likely to have a lower birth weight and a higher
number of births with a birth weight of less than 2500
grams. Interestingly, this finding is consistent with other
studies of assisted reproduction outcomes such as IVF/
ICSI. In most cases PGT conception is closest to natural conception and not assisted reproduction conception, with regard to the reproductive health of parents.
Parents who opt to undergo the most common form of
PGT, PGT-M, usually do not have fertility issues but are
concerned with passing a genetic disease to their children. However, in this study, the majority of PGT patients
had undergone PGT-A in which parents bear closer risk
and resemblance to couples undergoing other assisted
reproductive conception. PGT-A is usually used after
failed IVF cycles or because of other fertility issues, such
as advanced maternal age. It is therefore unsurprising that
the age of the PGT mothers was significantly higher than
the NC mothers, (P = 0.0001) as was the rate of preterm
birth and low birth weight in the PGT group, which is
commonly seen in other assisted reproduction outcome
studies (Banrjee, et. al. 2008).
The study performed by Desmyttere et. al. (2012),
found that the average birthweight for PGT singletons
and PGT multiples with a very low birth weight (<1500 g)
was comparable with the ICSI children. However, significantly more ICSI multiples presented a low birthweight
(<2500 g), more specifically 268 (17.8%) ICSI compared
to 161 (16.2%) PGT babies. Again, this may be due to the
fertility status of the parents, since the ratio of infertile
couples was higher in the ICSI cohort than in the PGT
cohort. Measurements of height and head circumference showed no significant differences between the two
groups. Mean gestational age at birth for PGT singletons,
twins and triplets showed no difference compared to the
ICSI group. Additionally, the number of PGT singletons
and multiples born prematurely (<37 weeks) showed
no differences compared with their ICSI counterparts
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(all P-values > 0.05). Twenty-one ICSI and four PGT singletons versus 67 ICSI and 31 PGT multiples were born
very prematurely (<32 weeks) which is not significant
(P = 0.056 and P = 0.43 for singletons and multiples).
Admission after delivery to the neonatal intensive care
unit was comparable for both the PGT and ICSI groups
for singletons and multiples. These results show that singletons and multiples born after a PGT embryo biopsy
had similar neonatal outcomes in terms of auxological
data, gestational age and neonatal hospital admission, to
the control group of singletons and multiples with no
embryo biopsy. Additionally, in this study, PGT multiples
appear to be at a lower risk for low birthweight when
compared to IVF/ ICSI multiples.
The study by Liebaers et al. (2010) found that in the
PGT cohort, 11.5% of singletons and 65.7% of multiples
were born premature. In the ICSI cohort, 8.4% of singletons and 57.9% of multiples were born premature. Low
birthweight was observed in 7.4% of PGT singletons and
very low birth weight in 3 (0.8%) PGT children. Multiple
PGT births of a low birth weight (62.5%) were significantly lower than ICSI multiple births (49.4%). Very low
birth weight was observed in 19 of the PGT multiples.
These results suggest that a three day PGT biopsy does
not seem to add significant health risks for singleton PGT
children since when these results were compared to the
data collected from IVF/ ICSI children born within the
same years, gestational ages and birthweights were similar.
However, PGT multiples appeared to be at an increased
risk of low birthweight, preterm birth, and perinatal death
compared to ICSI multiples. Multiple pregnancies should
be avoided when possible and may potentially solve problems especially regarding perinatal death.
A similar study looked at whether women who conceived after PGT and their children have greater risks of
adverse pregnancy and birth outcomes compared with
children conceived spontaneously or after IVF with or
without intracytoplasmic sperm injection (ICSI). The study
looked at factors such as pre-eclampsia, preterm primary rupture of membranes, placenta previa, abruption of
placenta, preterm birth, low birth weight, major malformations, and neonatal admission. It was found that compared to women conceiving spontaneously, women who
had undergone PGT or IVF/ ICSI were older, more often
uniparous, had a higher BMI and smoked less often during
pregnancy. The children conceived after IVF/ ICSI had a
lower birth weight, shorter gestational age, longer neonatal
hospital admission and an increased risk of preterm birth
and malformations. Children born after PGT had a comparable risk of the same complications, however, the results
were just short of statistical significance for many of the

outcomes. Nonetheless, PGT children were found to have
a significant increased risk of preterm birth, shorter gestation, and longer neonatal hospital admission. The study
also looked at the difference in outcomes between PGTM, PGT-A and PGT-SR. When compared to NC children,
PGT-SR and PGT-A children did not have an increased risk
of adverse neonatal outcomes. When compared to IVF/
ICSI children, PGT-SR and PGT-A children had comparable
neonatal outcomes and were found to have a higher mean
birth weight. However, compared to NC children, children
born after PGT-M had a significantly lower birth weight,
shorter gestation and increased risk for longer neonatal
hospital admission. These results show an increased risk
of neonatal complications in PGT pregnancies when compared to spontaneous pregnancies. However, the risk of
adverse outcomes was generally comparable to IVF/ ICSI
pregnancies, indicating that the actual embryo biopsy does
not add additional risks. Additionally, when separating
PGT-SR and PGT-A pregnancies from PGT-M pregnancies,
adverse neonatal outcomes were only found in children
conceived through PGT due to a parental monogenetic
disorder (PGT-M) and not in children born after PGT-SR
and PGT-A. These results make it likely that the risk of adverse outcomes is not related to PGT itself, but to the underlying condition of the parents.These factors can include
the known genetic disorder, associated comorbidities or
any medications taken during pregnancy. (Bay, et. al. 2016)
A study compared the growth data at birth and two
years for 70 singletons born after PGT, ICSI or natural
conception. Children were matched for gender, language,
birth order and maternal education level. At birth, height
and head circumference data were comparable for the
PGT, IVF/ ICSI and NC cohorts.While the PGT singletons
tended to have a lower birthweight and gestational age
compared with the NC children, these differences did not
reach statistical significance. When comparing children
born after a biopsy of one or two blastomeres, weight,
height and head circumference measurements were
comparable for the two groups. Additionally, admission
to a neonatal ward was comparable in the three conception groups and PGT children did not experience more
hospital stays for medical reasons than the ICSI and NC
groups. PGT children were also reported to have undergone more complementary examinations (with normal
results) compared with NC and ICSI babies. However,
this is probably due to precautionary measures for ‘specially conceived’ children (Desmyttere, et. al. 2009).
Obstetric Outcomes
In the study performed by Eldar-Geva et. al. (2014), the incidence of pregnancy complications such as hypertension
9
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and diabetes were similar in the PGT, IVF/ ICSI and NC
groups. Of the PGT mothers 1% had hypertension and
2% had gestational diabetes. Of the ICSI and NC mothers, 1% had hypertension and 6% had diabetes, and 3%
had hypertension and 4% had diabetes, respectively.
Additionally, the differences in mode of delivery for singleton pregnancies was statistically significant. The cesarean delivery rates were 28.5% in the PGT group, 31.6% in
the ICSI group, and 11.0% in the NC group (P<.005). As
discussed earlier, the cesarean rate for the PGT cohort
was more than double the rate of the NC group in this
study and was probably due to the fact that women with
autosomal dominant diseases in the PGT cohort opted
to have a cesarean delivery at 37 to 38 weeks.
In the study performed by Desmyttere et. al. (2009),
increased rates of cesarean births were found when PGT
mothers were compared to IVF/ ICSI mothers. Results
also showed that when compared to NC mothers, PGT
mothers experienced more pregnancy complications
such as gestational diabetes, thyroid pathology, pregnancy-induced hypertension, placental pathology and premature contractions. However, there were no differences
regarding pregnancy complications when comparing PGT
and IVF/ ICSI mothers.
In the study performed by Bay et. al. (2016) the IVF/
ICSI cohort showed an increased risk of placental disorders, including placenta previa, pre-eclampsia, placental
abruption, preterm primary rupture of membranes, and
induction of labor or cesarean section. The women who
gave birth after PGT had a comparable risk for most of
the same complications when compared to the NC cohort, although for most of the outcomes the results were
just short of statistical significance. However, the PGT
cohort did show a significant increased risk of placenta
previa and cesarean section. Because the risk of adverse
outcomes was generally comparable to IVF/ ICSI pregnancies in many of these studies, it seems like the actual
embryo biopsy does not add additional risks.
When the study separated PGT-M subjects from PGT-A
and PGT-SR subjects interesting results emerged. PGT-SR
and PGT-A children did not have an increased risk of any
adverse obstetric outcomes, except for a higher risk of
placenta previa when compared to NC controls. When
compared to IVF/ ICSI children, PGT-SR and PGT-A children had comparable obstetric outcomes. However,
compared to NC children, children born after PGT-M
had a significantly increased risk for preterm primary
rupture of membranes, cesarean section and placenta
previa. Again, these results make it likely that the risk of
adverse outcomes is not related to PGT itself, but to the
underlying condition of the parents. However, there was
10

a consistent increased risk of placenta previa after both
PGT and IVF/ICSI, which suggests that parental factors do
not explain all the adverse outcomes.
Follow up Study
Growth
A study assessed whether PGT causes adverse outcomes
by comparing findings at birth and at 2 years of age for
singletons born after PGT, IVF/ ICSI, and NC. The study
also investigated whether the body size of children born
after biopsy of one blastomere was different from that of
children born after biopsy of two blastomeres. Subjects
in all groups were matched for gender, maternal educational level, mother tongue and birth order. A strength to
this study is that all children were examined by the same
pediatrician in a standardized way. At a two year follow
up, weight, height, head circumference, and waist and arm
measurements were comparable for the three cohorts.
These results show that PGT singletons do not appear
to be at a higher risk of growth retardation compared
with IVF/ ICSI and NC singletons. In PGT children, the
mean BMI was statistically significantly lower compared
with NC children. Growth parameters of the PGT children born after biopsy of one blastomere were comparable to children born after a biopsy of two blastomeres.
(Desmyttere, et. al. 2009)
The study performed by Banerjee et. al. (2008) found similar results. When assessed at the mean age of 18 months,
growth parameters for all PGT children were within the
normal range including the children who had been born
preterm and/ or with a low birthweight. Furthermore,
Desmyttere et. al. (2009) found that in their follow up study
that rates of chronic disease and chronic use of medication
were similar between PGT and NC children.
Socio-emotional and Language Development
A study was performed to assess the socio-emotional
and language development of children at age two born
after PGT, IVF/ ICSI, and NC, as well as parental wellbeing. A small number of children (n= 10) that were born
before between 33-36 weeks gestations were included
in the study and were equally distributed among the cohorts. Most of these children had a normal birth weight
(<2500 g), and none of them had a very low birth weight
or obtained an Apgar score of less than nine after ten
minutes. Twins were excluded from the study because
developmental outcome is affected by prematurity and
low birth weight, which are known to be more common in twins and triplets. NC and ICSI controls were
matched for gender, maternal education level, native language, and birth order. All members of the PGT cohort
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had a blastomere biopsy at the eight-cell stage. Parents
were asked to complete the Short Temperament Scale
for Toddlers (STST) and the Child Behavioral Checklist
(CBCL) in order to assess the child’s socio-emotional
development. The STST, placed children into one of three
temperament categories, easy, average or difficult. The
CBCL answers questions about the child’s emotional and
behavioral problems. Parents answered if the problem
presented is ‘not true’, ‘somewhat or sometimes true’ or
‘very true or often true’ of their child, with item scores
of 0, 1 or 2. A total score of 60 is at the bottom of
the clinical range, and a score of 64 or more represents
larger issues. Language comprehension and production
were rated according to the McArthur Communicative
Developmental Inventories.
The CBCL scores showed no difference in the proportion of children above the clinical threshold points
according to mothers and fathers. After controlling for
socio-demographic variables, PGT and ICSI mothers
reported significantly fewer problems than the NC cohort. According to the STST scores, a similar proportion
of parents from all three conception groups reported
their child’s temperament as easy, average or difficult.
This remained true even after controlling for socio-demographic variables. Additionally, the mean Language
Comprehension score and Language Production score
did not differ significantly among the cohorts.
This study had some weaknesses. Firstly, results were
obtained exclusively from parental reports and more valid
reports could have been obtained from a multiple informant approach.Additionally, the PGT cohort had members
that had undergone PGT-M and PGT-A. Since these procedures are usually done for different reasons, PGT-M and
PGT-A populations have different medical histories and
family backgrounds, which may influence socio-emotional
and language results (Nekkebroeck, et. al. 2008a).
Additionally, the study by Banerjee et al. (2008) found
that the PGT cohort had significantly higher scores on
the Hearing and Language subscale, than the NC group.
These studies suggest that PGT does not cause adverse
neurodevelopmental outcomes.
Mental and Psychomotor Development
In the study by Banjeree et al. (2008), children up to age
four were evaluated with a focus on neurodevelopmental
screening which was measured using the Griffiths Scales
of Mental Development. The mean Griffiths quotient for
both the PGT and NC groups were in the normal range
and did not differ significantly. The only significant differences were for the Locomotor subscale, where the PGT
group was significantly lower than the NC group.

A similar study aimed at assessing the mental and psychomotor developmental outcomes in two-year-old children conceived through PGT compared to children born
after IVF/ ICSI and natural conception (NC). ICSI and NC
controls were matched for gender, maternal education,
birth order, and native language. All PGT subjects had a
blastomere biopsy at the eight-cell stage of the embryo.
At two years of age, the children were all tested by a psychologist using the Dutch version of the Bayley Scales of
Infant Development (BSID). The psychologist was blinded
to the status of the subject’s conception while conducting the evaluation. Parents were questioned regarding
socio-demographic characteristics. The BSID consists
of two major scales. The mental scale measures visual
and auditory information procession, imitation, memory,
hand-eye coordination, and problem solving. The motor
scale appraises control of gross and fine motor skills.
There were no significant group differences regarding
mental and motor scale scores.Additionally, equal numbers
of PGT, ICSI, and NC subjects were represented in each
level (accelerated, normal, delayed) of psychomotor and
mental development. Interestingly, when compared across
all three cohorts, psychomotor and mental development
scores were very similar for males and females. However,
when compared within each cohort, ICSI boys obtained
lower scores on both scales than the ICSI girls (P = 0.061).
The mode of delivery had no impact on psychomotor or
mental development even after controlling for sociodemographic factors. (Nekkebroeck, et. al. 2008b).
From the results of these two studies, it can be concluded that the embryo biopsy done in PGT has no impact on the mental and psychomotor development of
two-year-old children, compared to ICSI and NC children
Parent-Child Relationship
The study by Banerjee et. al. (2008), used the Parental
Stress Index and the Parental Acceptance-Rejection
Questionnaire to assess differences in the parent-child
relationship. The Parental Stress Index, which asked parents about parental distress, parent–child dysfunctional
interaction, and the difficulty of the child, showed no
significant difference between the PGT and NC groups.
In the Parental Acceptance-Rejection Questionnaire,
the PGT group had significantly higher scores on the
warmth-affection subscale, and significantly lower scores
on the aggression-hostility and rejection subscales than
the NC group.
In another study parental stress and health status were
measured with the Parent Stress Index and the General
Health Questionnaire (GHQ). No differences in parental
stress were found for mothers and fathers among the
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three groups. However, after controlling for socio-demographic variables, the ICSI mothers and fathers reported
less stress from parenting (P = 0.048). These results are
similar to findings in other studies and may be because
greater efforts are made by ICSI parents to have a child
compared to parents who conceive naturally. Another
theory is that ICSI parents may be inclined to underreport behavioral issues because of their need to demonstrate their abilities as parents and move on from the
issue of infertility where they struggled. On the other
hand, there was an equal proportion from all three cohorts that experienced low, moderate or high levels of
parenting stress. Scores on the GHQ measuring parental
health were not significantly different, even after controlling for socio-demographic factors. Parents from all
three conception groups obtained similar scores on the
subscales: somatic symptoms, anxiety, social dysfunction
and severe depression. The results from these studies
imply that parents seem to cope with the extra stress
of PGT without it affecting the parent-child relationship
(Nekkebroeck, et. al. 2008a).
Conclusion
Overall, it does not seem that preimplantation genetic
testing causes adverse clinical outcomes. This is especially important since the majority of couples who undergo
PGT usually do not have fertility issues and have the option of natural conception with invasive prenatal testing.
The results of these research studies show no significant
increased risk of perinatal death or malformations, especially when compared to IVF/ ICSI births, indicating that
the embryo is able to recover from the cells removed
during the biopsy and it therefore adds no additional risk.
Furthermore, children conceived through PGT seem to
be on the same developmental level as their peers and
show no growth retardation in follow up studies. While
some studies show an increased risk of preterm delivery,
low birth weight and some obstetric outcomes, it is important to determine whether this is because of the embryo biopsy or because of the underlying health condition
of the parents such as the fertility issues or the genetic
disease for which they chose to undergo PGT in the first
place. However, since this technology is fairly new, there
are few follow up studies that investigate the long-term
effects of PGT. Additional follow up studies are necessary
to ensure the long-term safety of this technology. Future
studies can also investigate the specific outcomes for
each method of PGT, since most of the research is either
regarding a blastomere biopsy or combines all methods
of PGT in the PGT cohort. Furthermore, future studies
should focus on determining the outcome differences
12

between PGT-M, PGT-A and PGT-SR since parents who
undergo the different forms of PGT have different medical backgrounds which can affect the results of these
studies. Couples considering PGT should consult their
physician or a genetic counselor to determine whether
PGT is the correct option as well as which method of
PGT should be used.
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